Biofrontera Inc. (BFRI)
(Real Time Quote from BATS)
$1.28 USD
0.00 (0.00%)
Updated Sep 23, 2024 03:44 PM ET
After-Market: $1.28 0.00 (0.00%) 4:06 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.28 USD
0.00 (0.00%)
Updated Sep 23, 2024 03:44 PM ET
After-Market: $1.28 0.00 (0.00%) 4:06 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Zacks News
Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 138.46% and 72.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lineage Cell (LCTX) delivered earnings and revenue surprises of 25% and 10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 54.55% and 88.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -21.43% and 76.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 150% and 0.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Biofrontera Inc. (BFRI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Biofrontera Inc. (BFRI) Rating Upgrade to Buy
by Zacks Equity Research
Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biofrontera Inc. (BFRI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -19.46% and 0.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 8.33% and 44.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Kronos Bio, Inc. (KRON) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -4% and 25.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of -29.41% and 5.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biofrontera Inc. (BFRI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of 0% and 5.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 28.57% and 3.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 2.21% and 67.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 10.13% and 97.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -1.45% and 30.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biofrontera Inc. (BFRI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of 28.13% and 0.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 31.25% and 88.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?